×
The $7.50 central target reflects a single current, published price objective, not a multi-analyst consensus, because Aclarion, Inc. (ACON) has only one covering analyst. That analyst, Ascendiant Capital's Lucas Ward, maintains a Buy rating and raised his 12-month target from $7.00 to $7.50 in late May 2026, based on a net-present-value analysis.
The central target is $12, the arithmetic mean of six recent, attributable analyst price targets reviewed, rounded from approximately $11.70. The latest verified closing price is $9.35 (Nov. 10, 2026), implying a required gain of roughly 28% to reach $12.
The central $10 stock price target is the arithmetic mean of eight current analyst price targets, which range from $8.00 to $15.00. LifeMD, Inc. (LFMD) last closed at $1.74, meaning the stock would need to rise roughly 475% to reach the central target — an extremely large move.
LifeMD shares have declined roughly 34.5% over the last 30 days, falling from about $2.55 to near $1.67, extending a longer multi-month downtrend. The selloff accelerated after LifeMD disclosed it needed more time to file its quarterly report and correct historical financial statements.
Carlsmed (CARL) jumped +19.85% during the regular session, climbing from a $14.71 prior close to about $17.63. The move followed a flurry of post-earnings analyst price-target increases — BTIG to $26, Needham to $22, and Truist to $23, all maintaining Buy ratings — after the company's Q3 beat-and-raise.
The $19 central target is the arithmetic mean of five verified analyst price targets, which range from roughly $16 to $24. At a recent price near $16.05, reaching $19 implies an upside of roughly 18% — a substantial move that would require clearing the stock's 52-week high.
Carlsmed is scheduled to report its third quarter 2026 results after the market close on Tuesday, November 10, 2026. Wall Street consensus points to quarterly revenue of roughly $19.2 million, which would mark about 46% year-over-year (YoY) growth.
The central target of $8 is the rounded arithmetic mean of the verified analyst price targets collected for LFMD , which average roughly $8.13 across about eight analysts. The analyst range is unusually wide — approximately $5 to $15 — reflecting sharp disagreement and a year of aggressive downward revisions.
LFMD dropped from $2.10 to $1.95, a -7.14% decline, during regular market hours, extending the prior session's slide. The drop extends selling after the company's Form NT 10-Q disclosure that it must correct historical financials — over-recognized revenue and under-recognized costs for periods from 2024 through June 30, 2026 — and delay its 10-Q filing.
CARL slid from a prior close of $16.05 to $15.53, down -3.24%, during regular trading hours. No verified news or fundamental catalyst found — the decline is likely profit-taking and pre-earnings positioning after the prior session's +10.54% surge, with Q3 results due after today's close.
The central target used here is $8, based on a mean of current analyst price targets of about $8.13, rounded to a reader-friendly level. Individual 12-month targets range widely, from a low of $5 to a high of $15, reflecting sharp disagreement about the company's turnaround.
The central target of $46 is the arithmetic mean of five verified analyst price targets collected from firms including Barclays, Piper Sandler, Wells Fargo, Canaccord Genuity, and Citi. With Claritev Corporation (CTEV) shares trading near $24, reaching $46 would require a gain of roughly 90%, a very large move.
Revenue climbed 9.1% year over year to $268.3 million, surpassing consensus estimates of roughly $256 million. Net loss narrowed to $61.8 million, with a diluted loss of $3.64 per share, an improvement from the $4.23 loss reported a year earlier.
BrightSpring Health Services' 6.75% tangible equity units (BTSGU) climbed roughly 13% over the past 30 days, rising from about $199 in early October to approximately $225. The move was driven by a strong third-quarter report released October 30, in which revenue rose 26% to $4.2 billion and adjusted EBITDA jumped 42% to $228 million.
The central target of $7.00 is not an analyst consensus. It reflects a round-number resistance level discussed in public technical commentary, not a published price objective from Wall Street research. With the latest verified close near $5.14 , reaching $7.00 would require a rise of roughly 36% — a substantial move even for a volatile micro-cap.
ONMD shares rose roughly 32% over the trailing 30 days, rebounding from an October low near $3.61 to approximately $5.62. The advance followed preliminary third-quarter 2026 revenue of about $1 million and fourth-quarter revenue guidance of $12 million to $14 million.
The $255 objective used here is a technical milestone, not an analyst consensus: it represents a return to BTSGU's 52-week high of $255.51, set in mid-June 2026. BTSGU last closed near $212, meaning the move to $255 requires roughly 20% upside — a substantial, but not extreme, gain.
ONMD climbed from its previous close of $5.14 to about $5.40 during Monday's regular session, a gain of +5.01%. The move followed OneMedNet's announcement of roughly $18.76 million in year-to-date contracted bookings — nearly 14x full-year 2025 — plus a 13th channel-partner agreement adding about 25% to its sales funnel.
The $7.50 central target is a technical objective derived from public discussion, not an analyst consensus — no verifiable analyst price targets currently cover the stock. The target represents a recovery back toward and above the 200-day moving average near $7.09, a commonly watched milestone for micro-cap names.
DOCS is a profitable, high-margin digital network for physicians, while TTWO is a large video game publisher still generating GAAP net losses ahead of a major product catalyst. DOCS has faced decelerating growth and cautious forward guidance tied to pharmaceutical budget timing, pressuring its share price in recent periods.